Literature DB >> 3798566

Potentiation of adriamycin cytotoxicity in P388 murine leukemia sensitive and resistant to adriamycin by use of lonidamine and hyperthermia.

M Chitnis, M Adwankar.   

Abstract

The in vitro effect of adriamycin (ADR) and lonidamine alone and in combination, at 37 degrees C and 43 degrees C, was investigated on murine leukemia P388 sensitive (P388/S) and resistant (P388/ADR) to adriamycin. The sensitive and the resistant cells were exposed in vitro with and without the drugs for 1 h at 37 degrees C and 43 degrees C. These cells were inoculated ip (10(6) cells/mouse) into groups of BDF1 mice. Cytotoxic effect of the treatment was assessed on the basis of percentage increase in life span (% ILS) of these animals, compared to the animals receiving cells which did not receive any treatment but exposed only to 37 degrees C for 1 h. It was observed that exposure of P388/ADR cells to lonidamine or adriamycin alone at 43 degrees C for 1 h resulted in greater cell kill, thus enhancing the % ILS of the experimental animals receiving those cells, compared to that of mice receiving the cells exposed to the same drugs for 1 h at 37 degrees C. However, the combination of lonidamine (0.02 mM) and adriamycin (10 micrograms/ml) at 43 degrees C for 1 h showed more than a synergistic effect, resulting in a % ILS of 120. Similar results were seen in the case of P388/S; however, the observations pertaining to P388/ADR are encouraging, since the mode of treatment has reversed the acquired resistance of P388 leukemia cells to adriamycin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3798566     DOI: 10.1177/030089168607200503

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  3 in total

1.  In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines.

Authors:  S Savini; W Zoli; O Nanni; A Volpi; G L Frassineti; E Magni; A Flamigni; A Amadori; D Amadori
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts.

Authors:  M De Cesare; G Pratesi; A Giusti; D Polizzi; F Zunino
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

3.  Phase II study of lonidamine in metastatic breast cancer.

Authors:  P Pronzato; D Amoroso; G Bertelli; P F Conte; M P Cusimano; G B Ciottoli; M Gulisano; R Lionetto; R Rosso
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.